Launch of Tecentriq in 2L+ NSCLC in Japan
https://www.roche.com/dam/jcr:0bf6c9e1-0dff-4c56-a5e4-d06507543ed6/en/180418eTecentriq_Launch.pdf Read more
Tag: Roche
FDA grants Breakthrough Therapy Designation for Roche’s Hemlibra in haemophilia A without inhibitors
Basel, 17 April 2018 FDA grants Breakthrough Therapy Designation for Roche’s Hemlibra in haemophilia A without inhibitors Designation based on phase III HAVEN 3 study demonstrating Hemlibra prophylaxis significantly reduced bleeds compared to no prophylaxis First medicine to show superior efficacy compared to prior factor VIII prophylaxis in an intra-patient comparison Roche (SIX: RO, ROG;... Read more
FDA grants Breakthrough Therapy Designation for Roche’s Hemlibra in haemophilia A without inhibitors
Basel, 17 April 2018 FDA grants Breakthrough Therapy Designation for Roche’s Hemlibra in haemophilia A without inhibitors Designation based on phase III HAVEN 3 study demonstrating Hemlibra prophylaxis significantly reduced bleeds compared to no prophylaxis First medicine to show superior efficacy compared to prior factor VIII prophylaxis in an intra-patient comparison Roche (SIX: RO, ROG;... Read more
Roche to present new data at AAN highlighting extensive research for OCREVUS and expanding neuroscience pipeline
Basel, 16 April 2018 Roche to present new data at AAN highlighting extensive research for OCREVUS and expanding neuroscience pipeline Breadth of data will reinforce efficacy and safety of OCREVUS in relapsing and primary progressive multiple sclerosis and demonstrate its benefits in slowing disability progression, including new cognitive and biomarker results Important research in Alzheimer’s... Read more
Roche to present new data at AAN highlighting extensive research for OCREVUS and expanding neuroscience pipeline
Basel, 16 April 2018 Roche to present new data at AAN highlighting extensive research for OCREVUS and expanding neuroscience pipeline Breadth of data will reinforce efficacy and safety of OCREVUS in relapsing and primary progressive multiple sclerosis and demonstrate its benefits in slowing disability progression, including new cognitive and biomarker results Important research in Alzheimer’s... Read more
Roche to present data on TECENTRIQ (Atezolizumab) and data from across its cancer immunotherapy portfolio at the 2018 American Association of Cancer Research (AACR) Annual Meeting
Basel, 14 April 2018 Roche to present data on TECENTRIQ (Atezolizumab) and data from across its cancer immunotherapy portfolio at the 2018 American Association of Cancer Research (AACR) Annual Meeting Data highlight commitment to personalised cancer immunotherapy combinations that stimulate deep anti-cancer immune responses Updated data from the Phase III IMpower150 study shows clinically meaningful... Read more
Roche completes acquisition of Flatiron Health
Basel, 06 April 2018 Roche completes acquisition of Flatiron Health Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that it has completed the acquisition of Flatiron Health, a privately held healthcare technology and services company headquartered in New York City, US. Flatiron Health is a market leader in oncology-specific electronic health record (EHR) software as... Read more
Roche completes acquisition of Flatiron Health
Basel, 06 April 2018 Roche completes acquisition of Flatiron Health Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that it has completed the acquisition of Flatiron Health, a privately held healthcare technology and services company headquartered in New York City, US. Flatiron Health is a market leader in oncology-specific electronic health record (EHR) software as... Read more
Roche completes acquisition of Flatiron Health
Basel, 06 April 2018 Roche completes acquisition of Flatiron Health Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that it has completed the acquisition of Flatiron Health, a privately held healthcare technology and services company headquartered in New York City, US. Flatiron Health is a market leader in oncology-specific electronic health record (EHR) software as... Read more
Roche announces Japanese court ruled in favour of Chugai in Hemlibra patent litigation
Basel, 28 March 2018 Roche announces Japanese court ruled in favour of Chugai in Hemlibra patent litigation Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that a Japanese court (Tokyo District Court) ruled in favour of Chugai Pharmaceutical Co., Ltd, a member of the Roche Group, in the patent litigation case relating to Hemlibra® (emicizumab).... Read more